Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Regeneron Pharmaceuticals Inc's EYLEA (aflibercept) injection receives FDA approval for treatment of Diabetic Macular Edema (DME)


Tuesday, 29 Jul 2014 06:32pm EDT 

Regeneron Pharmaceuticals Inc:Says U.S. Food and Drug Administration (FDA) has approved EYLEA(aflibercept) Injection for treatment of Diabetic Macular Edema (DME).Recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections.Although EYLEA may be dosed as frequently as 2 mg every 4 weeks, additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks.